From cellular therapy to biologics: Non-viral delivery strategies for in vivo CAR-T engineering.

Wu S, Shen Y, Tong X, Nian S, Yang P

Open source

DOI
10.1016/j.critrevonc.2026.105587
Published
2026 Sep 7
Container
Critical reviews in oncology/hematology
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.critrevonc.2026.105587,
  title = {From cellular therapy to biologics: Non-viral delivery strategies for in vivo CAR-T engineering.},
  author = {Wu S and Shen Y and Tong X and Nian S and Yang P},
  year = {2026},
  journal = {Critical reviews in oncology/hematology},
  doi = {10.1016/j.critrevonc.2026.105587},
  url = {https://doi.org/10.1016/j.critrevonc.2026.105587}
}

RIS

TY  - JOUR
TI  - From cellular therapy to biologics: Non-viral delivery strategies for in vivo CAR-T engineering.
AU  - Wu S
AU  - Shen Y
AU  - Tong X
AU  - Nian S
AU  - Yang P
PY  - 2026
JO  - Critical reviews in oncology/hematology
DO  - 10.1016/j.critrevonc.2026.105587
UR  - https://doi.org/10.1016/j.critrevonc.2026.105587
ER  - 

APA

S, W., Y, S., X, T., S, N., & P, Y. (2026). From cellular therapy to biologics: Non-viral delivery strategies for in vivo CAR-T engineering.. Critical reviews in oncology/hematology. https://doi.org/10.1016/j.critrevonc.2026.105587

Source records